[Federal Register: January 12, 2006 (Volume 71, Number 8)]
[Notices]
[Page 2107-2108]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr12ja06-124]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF THE TREASURY
Submission for OMB Review; Comment Request
January 6, 2006.
The Department of Treasury has submitted the following public
information collection requirement(s) to OMB for review and clearance
under the Paperwork Reduction Act of 1995, Public Law 104-13. Copies of
the submission(s) may be obtained by calling the Treasury Bureau
Clearance Officer listed. Comments regarding this information
collection should be addressed to the OMB reviewer listed and to the
Treasury Department Clearance Officer, Department of the Treasury, Room
11000, 1750 Pennsylvania Avenue, NW., Washington, DC 20220.
DATES: Written comments should be received on or before February 13,
2006 to be assured of consideration.
[[Page 2108]]
Internal Revenue Service (IRS)
OMB Number: 1545-1505.
Type of Review: Extension.
Title: Orphan Drug Credit.
Form: IRS form 8820.
Description: Filers use this form to elect to claim the orphan drug
credit, which is 50% of the qualified clinical testing expenses paid or
incurred with respect to low or unprofitable drugs for rare diseases
and conditions, as designated under section 526 of the Federal Food,
Drug, and Cosmetic Act.
Respondents: Business or other for-profit.
Estimated Total Burden Hours: 511 hours.
Clearance Officer: Glenn P. Kirkland, (202) 622-3428, Internal
Revenue Service, Room 6516, 1111 Constitution Avenue, NW., Washington,
DC 20224.
OMB Reviewer: Alexander T. Hunt, (202) 395-7316, Office of
Management and Budget, Room 10235, New Executive Office Building,
Washington, DC 20503.
Michael A. Robinson,
Treasury PRA Clearance Officer.
[FR Doc. E6-197 Filed 1-11-06; 8:45 am]
BILLING CODE 4810-01-P